Loading...
XNAS
TRAW
Market cap7mUSD
Oct 08, Last price  
0.48USD
1D
0.27%
1Q
-36.80%
Jan 2017
-100.00%
IPO
-100.00%
Name

Onconova Therapeutics Inc

Chart & performance

D1W1MN
XNAS:TRAW chart
P/E
0.80
P/S
2.62
EPS
0.60
Div yield, %
—
Shrs. gr., 5y
78.36%
Rev. gr., 5y
64.59%
Revenues
3m
+1,134.51%
1,487,00046,190,0004,753,000800,00011,456,0005,546,000787,0001,228,0002,183,000231,000226,000226,000226,000226,0002,790,000
Net income
9m
P
-30,314,000-33,865,000-64,863,000-63,682,000-23,979,000-19,667,000-24,092,000-20,573,000-21,503,000-25,157,000-16,163,000-18,964,000-18,948,000-54,674,0009,170,000
CFO
-18m
L-38.96%
-14,171,0001,633,000-61,384,000-57,648,000-31,313,000-15,813,000-23,820,000-22,696,000-20,831,000-23,075,000-19,487,000-16,294,000-17,932,000-29,792,000-18,185,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

The Fund seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of Onto Innovation Inc. (ONTO). The Fund will invest at least 80% of the value of its net assets, in financial instruments that provide leveraged exposure to the Underlying Security.

Key people

Steven M. Fruchtman
President, Chief Executive Officer, Director · since 2019
Mark Guerin
Chief Financial Officer · since 2016
Manoj Maniar
Senior Vice President - Product Development · since 2005
Henry S. Bienen
Director · since 2009
Jerome E. Groopman
Director · since 2013
Viren Mehta
Director · since 2004
E. Premkumar Reddy
Director · since 1999
Jack Stover
Director · since 2016
Anne M. VanLent
Director · since 2013
James J. Marino
Independent Director · since 2015
URL
https://www.onconova.com/
IPO date
Jul 25, 2013
Employees
16
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
Wilmington, DE 19808
US
Headquarters
12 Penns Trail
Newtown, PA 18940
US
Previous name
ONCONOVA THERAPEUTICS, INC.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT